ABC | Volume 113, Nº4, October 2019

Updated Updated Cardiovascular Prevention Guideline of the Brazilian Society Of Cardiology – 2019 Arq Bras Cardiol. 2019; 113(4):787-891 247. Stone SL, Kristeller JL Attitudes of adolescents toward smoking cessation. Am J Prev Med. 1992;8(4):221-5. 248. Meier KS. Tobacco truths: the impact of rolemodels on children's attitudes toward smoking. Health Educ Q. 1991;18(2):173-82. 249. Sussman S, Dent CW, Mestel-Rauch J, Johnson CA, HansenWB, Flay BR. Adolescent nonsmokers, triers, and regular smokers' estimates of cigarette smoking prevalence: when do overestimations occur and bywhom? J Appl Soc Psychol. 1988;18(7):537-51. 250. Hollis JF, PolenMR, Lichtenstein E, Whitlock EP. Tobacco use patterns and attitudes among teens being seen for routine primary care. Am J Health Promot. 2003;17(4):231-9. 251. LeMaistre C. Tobacco by the numbers. In: Texas Medicine; 1995. p.42. 252. 2012 US Surgeon General's Report: Preventing Tobacco Use Among Youth and Young Adults.[Internet]. [Cited in 2018 Jun 10]. Available from: https://www.cdc.gov/ ,=7 253. Kaufman NJ, Castrucci BC, Mowery PD, Gerlach KK, Emont S, Orleans CT. Predictors of change on the smoking uptake continuum among adolescents. Arch Pediatr Adolesc Med. 2002;156(6):581-7. 254. Young TL, Rogers KD. School performance characteristics preceding onset of smoking in high school students. Am J Dis Child. 1986;140(3):257-9. 255. Acierno R, Kilpatrick DG, Resnick H, Saunders B, De Arellano M, Best C. Assault, PTSD, family substance use, and depression as risk factors for cigarette use in youth: findings from the National Survey of Adolescents. J Trauma Stress. 2000;13(3):381-96. 256. Siqueira L, Diab M, Bodian C, Rolnitzky L. Adolescents becoming smokers: the roles of stress and coping methods. J Adolesc Health. 2000;27(6):399-408. 257. Myers MG, Brown AS. Smoking and health in substance-abusing adolescents: a two-year follow-up. Pediatrics. 1994;93(4):561-6. 258. Klein JD, Camenga DR. Tobacco prevention and cessation in pediatric patients. Pediatr Rev. 2004;25(1):17-26. 259. BRASIL. Ministério da Saúde. InstitutoNacional do Câncer. Coordenação de Prevenção e Vigilância. Abordagem e Tratamento do Fumante – Consenso 2001. Rio de Janeiro; 2001. 260. Ismael, SMC. Efetividade da terapia cognitivo-comportamental na terapêutica do tabagista [tese]. São Paulo: Universidade de São Paulo, Faculdade de Medicina; 2007. 261. Clinical Practice Guideline Treating Tobacco Use and Dependence 2008 Update Panel, Liaisons, and Staff. A clinical practice guideline for treating tobacco use and dependence: 2008 update. AU.S. Public Health Service Report. Am J Prev Med. 2008;35(2):158-76. 262. Rangé B (org). Psicoterapias cognitivo-comportamentais: umdiálogo com a psiquiatria. Porto Alegre: Artmed; 2001. 263. Prochaska JO, DiClementeCC, Norcross JC. In searchhowpeople change: applications to addictive behaviors. Am Psychol. 1992;47(9):1102-14. 264. Miller WR, Rollnick S. Entrevista motivacional. Porto Alegre: Artmed, 2001. p. 30-42. 265. Fagerström KO, Schneider NG. Measuring nicotine dependence: a review of the Fagerström Tolerance Questionnaire. J Behav Med. 1989;12(2):159-82. 266. Rosemberg J. Nicotina: droga universal. São Paulo: S.E.S./CVE; 2003. 267. Souza EST, Crippa JAS, Pasian SR, Martinez JAB. Escala razões para fumar modificada: tradução e adaptação cultural para o português para uso no Brasil e avaliação da confiabilidade teste-reteste. J Bras Pneumol. 2009;35(7):683-9. 268. National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health. The Health Consequences of Smoking-50 Years of Progress: A Report of the Surgeon General. Atlanta: Centers for Disease Control and Prevention ;2014. 269. Jha P, Ramasundarahettige C, Landsman V, Rostron B, ThunM, Anderson RN, et al. 21st-centuryhazards of smoking and benefits of cessation in the United States. N Engl J Med. 2013;368(4):341-50. 270. Benowitz NL, Pipe A, West R, Hays JT, Tonstad S, McRae T, et al. Cardiovascular safety of varenicline, bupropion, and nicotine patch in smokers: a randomized clinical trial. JAMA Intern Med. 2018;178(5):622-31. 271. Singh S, Loke YK, Spangler JG, Furberg, CD. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ. 2011;183(12):1359-66. 272. Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T, Lawrence D, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotinepatch insmokerswithandwithoutpsychiatricdisorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet. 2016;387(10037):2507-20. 273. Ussher MH, Taylor A, Faulkner G. Exercise interventions for smoking cessation. Cochrane Database Syst Rev. 2012 Jan 18;1:CD002295. 274. Stead LF, Lancaster T. Behavioural interventions as adjuncts to pharmacotherapy for smoking cessation. Cochrane Database Syst Rev. 2012 Dec 12;12:CD009670. 275. Stead LF, Perera R, Bullen C, Mant D, Hartmann-Boyce J, Cahill K, et al. Nicotine replacement therapy for smoking cessation. CochraneDatabase Syst Rev. 2012 Nov 14;11:CD000146. 276. Scharf D, Shiffman S. Are there gender differences in smoking cessation, with and without bupropion? Pooled- and meta-analyses of clinical trials of Bupropion SR. Addiction. 2004;99(11):1462-9. 277. CahillK,SteadLF,LancasterT.Nicotinereceptorpartialagonistsforsmoking cessation. Cochrane Database Syst Rev. 2012 Apr 18;(4):CD006103. 278. Aubin HJ, Bobak A, Britton JR, Oncken C, Billing CB Jr, Gong J, et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax. 2008;63(8):717-24. 279. Nides M, Glover ED, Reus VI, Christen AG, Make BJ, Billing CB Jr, et al. Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis. Am J Health Behav. 2008;32(6):664-75. 280. K o o b G F, Vo l k o w ND. N e u r o c i r c u i t r y o f a d d i c t i o n . Neuropsychopharmacology. 2010;35(1):217-38. 281. Food Drug Administration. (FDA) [Internet]. United States Food and Drug Administration 2008 Information for Healthcare Professionals: Varenicline (marketed as Chantix). NewHampshire: FDA. [Cited in 2012 Jan 12] Available from: https://www.fda.gov/drugs/postmarket-drug- safety-information-patients-and-providers/varenicline-marketed-chantix- information. 282. Singh S, Loke YK, Spangler JG, Furberg CD. Furberg. Risk of serious adverse cardiovascular events associatedwith varenicline: a systematic reviewand meta-analysis. CMAJ. 2011;183(12):1359-66. 283. Prochaska JJ, Hilton JF. Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. BMJ. 2012 May 4;344:e2856. 284. Rigotti NA, Pipe AL, Benowitz NL, Arteaga C, Garza D, Tonstad S. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation. 2010;121(2):221-9. 285. Ebbert JO, Croghan IT, Sood A, Schroeder DR, Hays JT, Hurt RD. Varenicline and bupropion sustained-release combination therapy for smoking cessation. Nicotine Tob Res. 2009;11(3):234-9. 286. HealthUSNIo Clinical Trials.gov Retrieved 2December 2011, fromhttp:// clinicaltrials.gov/ct2/results?term=varenicline+bupropion&recr=Open 287. Henningfield JE, Shiffman S, Ferguson SG, Gritz ER. Tobacco dependence and withdrawal: Science base, challenges and opportunities for pharmacotherapy. Pharmacol Ther. 2009;123(1):1-16. 876